Solid Biosciences Inc. (NASDAQ:SLDB) Receives $16.17 Consensus PT from Analysts

Solid Biosciences Inc. (NASDAQ:SLDB) has received a consensus recommendation of “Buy” from the nine research firms that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $16.17.

A number of brokerages have commented on SLDB. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Monday, May 20th. Leerink Partnrs raised shares of Solid Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 24th. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price target on shares of Solid Biosciences in a research report on Friday, June 21st. JPMorgan Chase & Co. raised shares of Solid Biosciences from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $10.00 to $15.00 in a research report on Monday, July 15th. Finally, Barclays cut their price objective on shares of Solid Biosciences from $21.00 to $18.00 and set an “overweight” rating on the stock in a research report on Thursday, May 16th.

Hedge Funds Weigh In On Solid Biosciences

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers bought a new position in Solid Biosciences in the 2nd quarter valued at about $191,000. Vestal Point Capital LP bought a new position in Solid Biosciences in the 4th quarter valued at about $209,000. Acadian Asset Management LLC bought a new position in Solid Biosciences in the 2nd quarter valued at about $379,000. Bank of New York Mellon Corp bought a new position in Solid Biosciences in the 2nd quarter valued at about $392,000. Finally, Vanguard Group Inc. lifted its position in Solid Biosciences by 283.9% in the 1st quarter. Vanguard Group Inc. now owns 1,244,575 shares of the company’s stock valued at $16,578,000 after acquiring an additional 920,404 shares in the last quarter. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Stock Performance

Shares of SLDB opened at $7.99 on Wednesday. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $306.66 million, a P/E ratio of -2.03 and a beta of 1.84. The firm’s fifty day simple moving average is $7.62 and its two-hundred day simple moving average is $9.12. Solid Biosciences has a 12 month low of $1.81 and a 12 month high of $15.05.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, analysts predict that Solid Biosciences will post -2.71 EPS for the current year.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.